Angelman Syndrome clinical trials at University of California Health
4 in progress, 2 open to eligible people
GTX-102 in Pediatric Subjects with AS
open to eligible people ages 4-17
The primary objective of this study is to evaluate the effect of GTX-102 in cognitive function in participants with Angelman Syndrome (AS).
at UCSD UCSF
Angelman Syndrome Natural History Study
open to all eligible people
The goal of this study is to conduct a prospective, longitudinal natural history study of children and adults with Angelman Syndrome using investigator-observed and parent-reported outcome measures to obtain data that will be useful for future…
at UCSD
(PK) and Pharmacodynamics (PD) of RO7248824 in Participants With Angelman Syndrome (AS)
Sorry, in progress, not accepting new patients
This is a phase I, multicenter, non-randomized, adaptive, open-label, multiple ascending, intra-participant, dose-escalation study with a long-term extension (LTE) part and an optional open-label extension (OOE) part. The objective of the study is…
at UCLA
Long-term Extension of GTX-102 in Angelman Syndrome
Sorry, accepting new patients by invitation only
The primary objective of the study is to evaluate the long-term safety profile of GTX-102 in participants with Angelman Syndrome (AS)
at UCLA UCSD
Our lead scientists for Angelman Syndrome research studies include Elliott Sherr Rajsekar R. Rajaraman, MD, MS.
Last updated: